PALI
Palisade Bio, Inc.
$1.95
-0.06
(-2.99%)
Mkt Cap
338.48M
Volume
3,257,691
52W Range
0.53-2.86
Sector
Healthcare
Beta
1.53
EPS (TTM)
-1.06
P/E Ratio
-7.80
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250,000 | 0 | 0 | 0 | 15,394 | 260,000 | 260,000 | 16,246 | 10,417 | 18,833 |
| Net Income | (16.78M) | (14.44M) | (12.30M) | (14.26M) | (26.62M) | (10.32M) | (8.35M) | (4.92M) | (15.67M) | (21.07M) | (20.90M) | (22.63M) |
| EPS | -0.30 | -10.19 | -27.01 | -16.53 | -2144.25 | -186.00 | -14.78 | -18.02 | -71.59 | -126.11 | -197.36 | -225.20 |
| Free Cash Flow | (10.85M) | (12.19M) | (11.14M) | (13.37M) | (14.77M) | (4.77M) | (7.26M) | (7.69M) | (13.51M) | (15.78M) | N/A | N/A |
| FCF / Share | -0.19 | -8.61 | -24.42 | -15.19 | -1190.12 | -5.74 | -59.27 | -28.16 | -61.74 | -1890.62 | N/A | N/A |
| Operating CF | (10.85M) | (12.19M) | (11.13M) | (13.36M) | (14.77M) | (4.77M) | (7.26M) | (7.69M) | (13.42M) | (15.62M) | N/A | N/A |
| Total Assets | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M | 3.02M | 6.58M | 7.68M | 13.88M | 22.60M | N/A | N/A |
| Total Debt | 71,000 | 169,000 | 369,000 | 404,000 | 199,000 | 1.42M | 288,543 | 5.04M | 0 | 3.71M | N/A | N/A |
| Cash & Equiv | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M | 713,000 | 5.11M | 5.79M | 6.67M | 15.19M | N/A | N/A |
| Book Value | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M | (7.10M) | 5.13M | 6.05M | 8.52M | 11.33M | N/A | N/A |
| Return on Equity | -0.13 | -1.93 | -1.09 | -1.14 | -3.61 | N/A | -1.63 | -0.81 | -1.84 | -1.86 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.60M) | (8.90M) | (2.87M) | (2.78M) | (2.23M) | (3.34M) | (3.49M) | (4.08M) | (3.53M) | (2.97M) | (3.60M) | (3.39M) |
| EPS | -0.05 | -0.06 | -0.38 | -0.58 | -0.46 | -0.57 | -2.32 | -3.32 | -4.59 | -0.51 | -7.38 | -7.93 |
| Free Cash Flow | (3.89M) | (3.14M) | (3.55M) | (1.82M) | (2.33M) | (2.38M) | (3.13M) | (3.50M) | (3.18M) | (2.75M) | (2.66M) | (2.20M) |
| FCF / Share | -0.02 | -0.06 | -0.48 | -0.38 | -0.49 | -0.41 | -0.54 | -0.60 | -4.14 | -0.47 | -5.44 | -0.34 |
| Operating CF | (3.89M) | (3.14M) | (3.55M) | (1.82M) | (2.33M) | (2.38M) | (3.13M) | (3.50M) | (3.18M) | (2.75M) | (2.66M) | (2.20M) |
| Total Assets | 133.31M | 134.34M | 6.97M | 6.67M | 8.19M | 10.88M | 9.34M | 12.87M | 12.65M | 14.05M | 17.07M | 18.29M |
| Total Debt | 0 | 71,000 | 211,000 | 338,000 | 58,000 | 169,000 | 357,000 | 503,000 | 183,000 | 369,000 | 498,000 | 677,000 |
| Cash & Equiv | 132.63M | 133.38M | 5.23M | 5.42M | 7.23M | 9.82M | 8.04M | 11.35M | 11.28M | 12.43M | 15.31M | 16.40M |
| Book Value | 127.36M | 129.38M | 3.21M | 2.62M | 5.33M | 7.49M | 6.61M | 9.95M | 10.06M | 11.31M | 14.08M | 15.80M |
| Return on Equity | -0.08 | -0.07 | -0.89 | -1.06 | -0.42 | -0.45 | -0.53 | -0.41 | -0.35 | -0.26 | -0.26 | -0.21 |
PALI News
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts
Palisade Bio Announces Participation in Two Upcoming Investor Conferences